Haizheng Pharmaceutical (600267.SH): Completed the repurchase and actually repurchased 0.97% of the company's shares
Gelonghui, April 19, 丨 Haizheng Pharmaceutical (600267.SH) announced that on April 18, 2024, the company's third share repurchase plan was completed. It actually repurchased 11.6872 million shares, accounting for 0.97% of the company's total share capital. The highest repurchase price was 9.75 yuan/share, the lowest repurchase price was 7.17 yuan/share, the average repurchase price was 8.47 yuan/share, and the total capital used was 98.99.27 million yuan (excluding transaction fees).
Hisun Pharma's Unit Gets Nod for Pig Vaccine
Zhejiang Hisun Pharmaceutical's (SHA:600267) unit, Yunnan Biopharmaceutical, received approval for a pig vaccine from China's Ministry of Agriculture and Rural Affairs, the pharmaceutical company said
Haizheng Pharmaceutical (600267.SH): It has repurchased a total of 7.829,900 shares at a cost of 697.16,300 yuan
Gelonghui, April 1, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of March 31, 2024, the company had repurchased a total of 7.829,900 shares, accounting for 0.6482% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.17 yuan/share, and the total amount paid was 697.16,300 yuan (excluding transaction fees).
Further Weakness as Zhejiang Hisun Pharmaceutical (SHSE:600267) Drops 5.0% This Week, Taking Three-year Losses to 46%
Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns
Haizheng Pharmaceutical (600267.SH): 59.315 million restricted shares will be listed and circulated on March 25
Zhitong Finance App News, Haizheng Pharmaceutical (600267.SH) issued an announcement. The company's current stock listing type is non-public shares; the stock subscription method is offline, and the total number of shares currently in circulation is 599.315 million shares. The current stock listing circulation date is March 25, 2024.
Retail Investors Are Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Biggest Owners and Were Hit After Market Cap Dropped CN¥488m
Key Insights Significant control over Zhejiang Hisun Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions The to
Haizheng Pharmaceutical (600267.SH): A total cost of 697.16 million yuan to buy back 0.6482% of shares
Gelonghui, March 1, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of February 29, 2024, the company had repurchased a total of 7,829,900 shares, accounting for 0.6482% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.17 yuan/share, and the total amount paid was 69,716,268.41 yuan.
Haizheng Pharmaceutical (600267.SH): Oseltamivir phosphate API obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”
Gelonghui, Feb. 28: Haizheng Pharmaceutical (600267.SH) announced that Haizheng Pharmaceutical Nantong Co., Ltd., a wholly-owned subsidiary, received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for oseltamivir phosphate APIs approved and issued by the State Drug Administration on February 28, 2024. Oseltamivir phosphate is a precursor drug for its active metabolite (oseltamivir carboxylate). Oseltamivir carboxylate is a selective influenza virus neuraminidase inhibitor used in the treatment of influenza A and B in adults and children aged 1 year and over, as well as influenza A and B in adults and adolescents aged 13 and over
Benign Growth For Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) Underpins Stock's 27% Plummet
The Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) share price has fared very poorly over the last month, falling by a substantial 27%. The drop over the last 30 days has capped off a tough
Haizheng Pharmaceutical (600267.SH): A total cost of 568.487 million yuan to buy back 0.5% of shares
Gelonghui, January 31, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of January 31, 2024, the company had repurchased a total of 6,111,900 shares, accounting for 0.5060% of the company's total share capital. The highest purchase price was 9.75 yuan/share, the lowest price was 7.71 yuan/share, and the total amount paid was 56,848,689.65 yuan.
Haizheng Pharmaceutical (600267.SH) forecasted a net loss of 65 million to 95 million yuan in 2023, from profit to loss year-on-year
Haizheng Pharmaceutical (600267.SH) disclosed the 2023 annual results pre-loss announcement. The company expects to belong during the reporting period...
Fangzheng Securities: Domestic approval of luncanizumab is expected to accelerate the development of the Alzheimer's diagnosis and treatment market
Start a new era of AD from “symptomatic treatment” to “causal treatment”.
Are Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
With its stock down 18% over the past three months, it is easy to disregard Zhejiang Hisun Pharmaceutical (SHSE:600267). However, the company's fundamentals look pretty decent, and long-term financi
Haizheng Pharmaceutical (600267.SH): Cycloserine capsules passed generic drug consistency evaluation
Gelonghui, January 12丨Haizheng Pharmaceutical (600267.SH) announced that it has received the “Drug Supplement Application Approval Notice” for cycloserine capsules approved and issued by the State Drug Administration. The company's drug cycloserine capsules have passed the consistent evaluation of generic drug quality and efficacy. Cycloserine capsules are suitable for the treatment of active tuberculosis and extrapulmonary tuberculosis (including kidney tuberculosis) caused by tuberculosis bacteria that are sensitive to this drug and are not effective with first-line anti-tuberculosis drugs (such as streptomycin, isoniazid, rifampicin, and ethaminoethanol).
Haizheng Pharmaceutical (600267.SH): A total of 276,000 shares have been repurchased
Gelonghui, January 2, 丨 Haizheng Pharmaceutical (600267.SH) announced that as of December 31, 2023, the company had repurchased 276,000 shares, accounting for 0.0229% of the company's total share capital. The highest purchase price was 9.36 yuan/share, the lowest price was 9.11 yuan/share, and the total amount paid was RMB 2,533,732.00 (excluding transaction fees).
Haizheng Pharmaceutical (600267.SH): Currently working on some projects using synthetic biological techniques
Gelonghui, December 26丨Haizheng Pharmaceutical (600267.SH) stated on an interactive platform that the “Productivity Promotion Award” was established with the approval of the Ministry of Science and Technology and the National Science and Technology Award Office, and that Haizheng Pharmaceutical's “Key Technologies and Applications for Industrialization of the Chemistry and Biosynthesis of Anthracycline Antitumor Drugs” project won the first prize of the “2022 Productivity Promotion (Innovation and Development) Award”. The company has always attached importance to the application of microbial technology and enzyme catalysis technology in pharmaceutical process development, and has built genetic modification platforms for various strains such as actinomycetes, yeast, and Escherichia coli. In recent years, with the increasing maturity of gene editing and targeted evolution technology, research and development has accelerated
Haizheng Pharmaceutical (600267.SH): First repurchase of 147,000 shares
Gelonghui, December 26, 丨 Haizheng Pharmaceutical (600267.SH) announced that on December 26, 2023, the company repurchased 147,000 shares for the first time using centralized bidding transactions. The repurchased shares accounted for 0.01% of the company's total share capital. The highest purchase price was 9.14 yuan/share, the lowest price was 9.11 yuan/share, and the total amount paid was RMB 1,340,622.00 (not including transaction fees).
Are Investors Undervaluing Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) By 47%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Zhejiang Hisun Pharmaceutical fair value estimate is CN¥17.03 Current share price of CN¥9.07 suggests Zhejiang Hisun Pharmaceutical is potent
Haizheng Pharmaceutical (600267.SH): Plans to spend 50 million yuan to 100 million yuan to repurchase shares
Gelonghui December 22丨Haizheng Pharmaceutical (600267.SH) announced that the company plans to repurchase some public shares with its own funds through centralized bidding transactions for subsequent implementation of employee stock ownership plans. The total repurchase capital shall not be less than RMB 50 million and shall not exceed RMB 100 million (all inclusive); the repurchase price shall not exceed RMB 13/share (inclusive).
Hisun Pharmaceutical's Unit Gets Certification for Imported Drug From Pfizer
Zhejiang Hisun Pharmaceutical's (SHA:600267) unit, Hanhui Pharmaceutical, received an imported drug registration certificate from China's National Medical Products Administration for methylprednisolon
No Data